Biomarkers for early detection of breast cancer: What, when, and where?

Levenson, Victor

doi:10.1016/j.bbagen.2007.01.017

Cited by 113 publications

(85 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current serum markers identified for breast cancer, such as cancer antigens (CA)15-3 and 27.29, carcinoembryonic antigen and tissue polypeptide antigen, lack either prevalence, disease-related specificity or validated clinical values. [37][38][39][40][41] For instance, CA 27.29 is a serum marker currently used for breast cancer, but its sensitivity in primary breast cancer is only 7.6%. 42 This study found that AKR1B10 is overexpressed in more than 80% primary, metastatic and recurrent breast cancers as confirmed from different tissue resources and by different methods (RT-PCR, Western blot and immunohistochemistry).…”

Section: Discussionmentioning

confidence: 99%

AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker

Luo

Huang

et al. 2012

Intl Journal of Cancer

103

111

View full text Add to dashboard Cite

Aldo-keto reductase 1B10 (AKR1B10) is a secretory protein that is upregulated with tumorigenic transformation of human mammary epithelial cells. This study demonstrated that AKR1B10 was overexpressed in 20 (71.4%) of 28 ductal carcinomas in situ, 184 (83.6%) of 220 infiltrating carcinomas and 28 (87.5%) of 32 recurrent tumors. AKR1B10 expression in breast cancer was correlated positively with tumor size (p 5 0.0012) and lymph node metastasis (p 5 0.0123) but inversely with disease-related survival (p 5 0.0120). Univariate (p 5 0.0077) and multivariate (p 5 0.0192) analyses both suggested that AKR1B10, alone or together with tumor size and node status, is a significant prognostic factor for breast cancer. Silencing of AKR1B10 in BT-20 human breast cancer cells inhibited cell growth in culture and tumorigenesis in female nude mice. Importantly, AKR1B10 in the serum of breast cancer patients was significantly increased to 15.18 6 9.08 ng/ml [n 5 50; 95% confidence interval (CI), 12.60-17.76], with a high level up to 58.4 ng/ml, compared to 3.34 6 2.27 ng/ml in healthy donors (n 5 60; 95% CI, 2.78-3.90). In these patients, AKR1B10 levels in serum were correlated with its expression in tumors (r 5 0.8066; p < 0.0001). Together our data suggests that AKR1B10 is overexpressed in breast cancer and may be a novel prognostic factor and serum marker for this deadly disease.

show abstract

Section: Discussionmentioning

confidence: 99%

AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker

Luo

Huang

et al. 2012

Intl Journal of Cancer

103

111

View full text Add to dashboard Cite

show abstract

“…Therefore, research has been conducted to identify the critical biochemical changes in cancer and has led to advances in its detection and treatment [3]. The detection of tumor markers has a major importance for the diagnosis of the onset of breast cancer [4]. Tumor markers are substances that can be found in the body when cancer is present [5,6].…”

Section: Introductionmentioning

confidence: 99%

“…Tumor markers are substances that can be found in the body when cancer is present [5,6]. The biomarkers found in biological fluids, blood in particular, apparently hold the best promise for the development of screening assays [4]. A simple blood test that could detect these cancers in their earliest stages could prevent the deaths of millions of people and reduce the suffering of patients and their families and the cost to society.…”

Section: Introductionmentioning

confidence: 99%

Electrochemical immunosensor for the analysis of the breast cancer biomarker HER2 ECD

Marques

Subramanian

Nouws

et al. 2014

Talanta

View full text Add to dashboard Cite

a b s t r a c tHuman epidermal growth factor receptor 2 (HER2) is a breast cancer biomarker that plays a major role in promoting breast cancer cell proliferation and malignant growth. The extracellular domain (ECD) of HER2 can be shed into the blood stream and its concentration is measurable in the serum fraction of blood. In this work an electrochemical immunosensor for the analysis of HER2 ECD in human serum samples was developed. To achieve this goal a screen-printed carbon electrode, modified with gold nanoparticles, was used as transducer surface. A sandwich immunoassay, using two monoclonal antibodies, was employed and the detection of the antibody-antigen interaction was performed through the analysis of an enzymatic reaction product by linear sweep voltammetry. Using the optimized experimental conditions the calibration curve (i p vs. log[HER2 ECD]) was established between 15 and 100 ng/mL and a limit of detection (LOD) of 4.4 ng/mL was achieved. These results indicate that the developed immunosensor could be a promising tool in breast cancer diagnostics, patient follow-up and monitoring of metastatic breast cancer since it allows quantification in a useful concentration range and has an LOD below the established cut-off value (15 ng/mL).

show abstract

“…More recently, the use of autoantibodies toward autologous TAAs has been gathering momentum as these have been detected in the asymptomatic stage of cancer and may therefore serve as diagnostic biomarkers (27)(28)(29)(30)(31). In fact, autoantibodies have been found to precede the manifestation of clinical signs of tumor progression by several months to years (17,(32)(33)(34).…”

Section: Diagnostic Relevance Of Autoantibodies As Biomarkers In Cancermentioning

confidence: 99%

“…78), and NY-ESO-1 (79) were first discovered in patients with breast cancer. In fact, antibodies to HER2/neu (76) have been detected in patients with early-stage breast cancer but their presence has also been detected in other cancers, limiting their use as a diagnostic biomarker for breast cancer alone (28,30,80). An increase to 44% sensitivity and 97.6% specificity in breast cancer detection was achieved through the successive addition of the three TAAs p53, protein 16 (p16), and avian myelocytomatosis viral oncogene homolog (c-myc; ref.…”

Section: Breast Cancermentioning

confidence: 99%

Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

Zaenker

Ziman

2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

135

111

View full text Add to dashboard Cite

Current diagnostic techniques used for the early detection of cancers are successful but subject to detection bias. A recent focus lies in the development of more accurate diagnostic tools. An increase in serologic autoantibody levels has been shown to precede the development of cancer disease symptoms. Therefore, autoantibody levels in patient blood serum have been proposed as diagnostic biomarkers for early-stage diagnosis of cancers. Their clinical application has, however, been hindered by low sensitivity, specificity, and low predictive value scores. These scores have been shown to improve when panels of multiple diagnostic autoantibody biomarkers are used. A five-marker biomarker panel has been shown to increase the sensitivity of prostate cancer diagnosis to 95% as compared with 12.2% for prostate-specific antigen alone. New potential biomarker panels were also discovered for lung, colon, and stomach cancer diagnosis with sensitivity of 76%, 65.4%, and 50.8%, respectively. Studies in breast and liver cancer, however, seem to favor single markers, namely a-2-HS-glycoprotein and des-g-carboxyprothrombin with sensitivities of 79% and 89% for the early detection of the cancers. The aim of this review is to discuss the relevance of autoantibodies in cancer diagnosis and to outline the current methodologies used in the detection of autoantibodies. The review concludes with a discussion of the autoantibodies currently used in the diagnosis of cancers of the prostate, breast, lung, colon, stomach, and liver. A discussion of the potential future use of autoantibodies as diagnostic cancer biomarkers is also included in this review. Cancer Epidemiol Biomarkers Prev; 22(12); 2161-81. Ó2013 AACR.

show abstract

Biomarkers for early detection of breast cancer: What, when, and where?

Cited by 113 publications

References 124 publications

AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker

AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker

Electrochemical immunosensor for the analysis of the breast cancer biomarker HER2 ECD

Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

Contact Info

Product

Resources

About